Ray Dalio Castle Biosciences Inc Transaction History

Bridgewater Associates, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$18.08 - $30.0 $154,656 - $256,620	-8,554 Reduced 22.68%	29,167 $686,000
Q3 2022 Nov 10, 2022	BUY	$22.51 - $34.32 $28,024 - $42,728	1,245 Added 3.41%	37,721 $984,000
Q2 2022 Aug 11, 2022	BUY	$16.0 - $45.99 $69,968 - $201,114	4,373 Added 13.62%	36,476 $801,000
Q1 2022 May 13, 2022	BUY	$33.17 - $46.98 $254,712 - $360,759	7,679 Added 31.44%	32,103 $1.44 Million
Q4 2021 Feb 14, 2022	SELL	$39.06 - $67.58 $1,796 - $3,108	-46 Reduced 0.19%	24,424 $1.05 Million

Q3 2021 Nov 12, 2021	SELL	$60.13 - $77.6 $90,676 - $117,020	-1,508 Reduced 5.8%	24,470 $1.63 Million
Q2 2021 Aug 13, 2021	BUY	$50.07 - $76.78 $1.3 Million - $1.99 Million	25,978 New	25,978 $1.91 Million

162

25.3M

82.2K

150K

Ticker CSTL
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 26,297,000
Market Cap $559M
Description
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...

Get notified when there are updates to the investment portfolio of Bridgewater Associates, LP, based on Form 13F filings with the SEC.

Stay updated on Bridgewater Associates, LP and Ray Dalio with notifications on news.